TCR2 Therapeutics (TCRR) Reports Q1 Loss of $4.85

TCR2 Therapeutics (NASDAQ: TCRR) reported Q1 EPS of ($4.85), versus ($28.90) reported last year.

"In our first quarter as a public company, TCR2 has continued to execute our vision and objectives," said Garry Menzel, Ph.D., President and Chief Executive Officer of TCR2 Therapeutics. "During the quarter, we initiated our Phase 1/2 trial for TC-210, progressed TC-110 toward IND submission in the second half of 2019, and highlighted the differentiation of our novel TRuC-T cells in scientific presentations at Keystone Symposia on Cancer Immunotherapy, AACR, and CAR-T Congress USA. These preclinical studies underscore TRuC-T cells’ greater anti-tumor activity, longer persistence, and less cytokine release compared to CAR-T cells."

For earnings history and earnings-related data on TCR2 Therapeutics (TCRR) click here.

You May Also Be Interested In

• Intuitive Surgiical (ISRG) beats earnings, revenue expectations in Q1
• Glacier Bancorp (GBCI) Misses Q1 EPS by 3c
• Community West Bancshares (CWBC) Tops Q1 EPS by 7c